Cat. No.: HY-N1469

Kaurenoic acid

Customer Review

Based on 1 Customer Validation

Kaurenoic acid is a diterpene derived from Sphagneticola trilobata. Kaurenoic acid has antibacterial, anti-inflammatory, anticonvulsant, analgesic, and aortic vasodilating effects.

For research use only. We do not sell to patients.

Purity: 99.93%
CAS No.: 6730-83-2
Formula: C₂₀H₃₀O₂
Molecular Weight:302.45

Storage:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Kaurenoic acid Chemical Structure

CAS No.: 6730-83-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Kaurenoic acid is a diterpene derived from Sphagneticola trilobata. Kaurenoic acid has antibacterial, anti-inflammatory, anticonvulsant, analgesic, and aortic vasodilating effects^[1]^[2]^[3]^[4].

Cellular Effect

Cell Line	Type	Value	Description	References
A498	ED₅₀	47.97 μg/mL Compound: 2	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 8882434]
A549	ED₅₀	13.59 μg/mL Compound: 2	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 8882434]
B16-F10	IC₅₀	54.79 μM Compound: 6	Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
HaCaT	CC₅₀	108.6 μM Compound: 1	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33236902]
HEK293	IC₅₀	357 nM Compound: 1b	Inhibition of mouse 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay Inhibition of mouse 11beta-HSD1 expressed in HEK293 cell microsomes assessed as inhibition of [3H]cortisone conversion to [3H]cortisol by scintillation proximity assay	[PMID: 23747808]
HeLa	GI₅₀	>9.92 μM Compound: 1	Growth inhibition against human HeLa cells after 72 hrs by inverted microscopy Growth inhibition against human HeLa cells after 72 hrs by inverted microscopy	[PMID: 23353738]
HepG2	CC₅₀	192.4 μM Compound: 1	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 23353738]
HepG2	IC₅₀	50.72 μM Compound: 6	Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
HL-60	IC₅₀	44.11 μM Compound: 6	Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
HT-29	ED₅₀	31.39 μg/mL Compound: 2	Cytotoxicity against human HT29 cells after 7 days by MTT assay Cytotoxicity against human HT29 cells after 7 days by MTT assay	[PMID: 8882434]
HT-29	GI₅₀	>9.92 μM Compound: 1	Growth inhibition against human HT-29 cells after 72 hrs by inverted microscopy Growth inhibition against human HT-29 cells after 72 hrs by inverted microscopy	[PMID: 23353738]
K562	GI₅₀	>9.92 μM Compound: 1	Growth inhibition against human K562 cells after 72 hrs by inverted microscopy Growth inhibition against human K562 cells after 72 hrs by inverted microscopy	[PMID: 23353738]
K562	IC₅₀	72.53 μM Compound: 6	Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
LLC-MK2	CC₅₀	76.1 μM Compound: 7	Cytotoxicity against monkey LLC-MK2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against monkey LLC-MK2 cells after 96 hrs by sulforhodamine B assay	[PMID: 22440015]
LLC-MK2	EC₅₀	596 μM Compound: 7	Antitrypanosomal activity against Trypanosoma cruzi Y trymastigotes infected in monkey LLC-MK2 cells after 24 hrs by Brenner counter method Antitrypanosomal activity against Trypanosoma cruzi Y trymastigotes infected in monkey LLC-MK2 cells after 24 hrs by Brenner counter method	[PMID: 22440015]
LLC-MK2	IC₅₀	16.5 μM Compound: 7	Antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in monkey LLC-MK2 cells after 96 hrs by Geimsa staining method Antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in monkey LLC-MK2 cells after 96 hrs by Geimsa staining method	[PMID: 22440015]
LoVo	GI₅₀	>9.92 μM Compound: 1	Growth inhibition against human LoVo cells after 72 hrs by inverted microscopy Growth inhibition against human LoVo cells after 72 hrs by inverted microscopy	[PMID: 23353738]
MCF7	ED₅₀	1 μg/mL Compound: 2	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 8882434]
MIA PaCa-2	ED₅₀	22.13 μg/mL Compound: 2	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 8882434]
PANC-1	GI₅₀	>9.92 μM Compound: 1	Growth inhibition against human PANC1 cells after 72 hrs by inverted microscopy Growth inhibition against human PANC1 cells after 72 hrs by inverted microscopy	[PMID: 23353738]
PBMC	IC₅₀	0.002 μM Compound: 15	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry	[PMID: 25338180]
PBMC	IC₅₀	0.01 μM Compound: 15	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry	[PMID: 25338180]
PBMC	IC₅₀	7.7 μM Compound: 15	Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry	[PMID: 25338180]
PBMC	IC₅₀	80.77 μM Compound: 6	Cytotoxicity against concanavalin-A stimulated human PBMC after 72 hrs by alamar blue assay Cytotoxicity against concanavalin-A stimulated human PBMC after 72 hrs by alamar blue assay	[PMID: 24969014]
PC-3	ED₅₀	15.19 μg/mL Compound: 2	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 8882434]
RAW264.7	IC₅₀	>100 μM Compound: 1	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 20116261]
RAW264.7	IC₅₀	>25 μM Compound: 1	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release pretreated for 15 mins before LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide release pretreated for 15 mins before LPS challenge measured after 24 hrs by Griess method	[PMID: 21334121]
SH-SY5Y	CC₅₀	45.4 μM Compound: 1	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33236902]

In Vitro

Kaurenoic acid (10-100 μM, 60 min) concentration-dependently inhibits the contraction of endothelial-intact or -stripped rat aortic rings induced by adrenaline and KCl^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Kaurenoic acid (1-10 mg/kg, i.g., single dose) reduces peritonitis and pain induced by lipopolysaccharides (HY-D1056) in mice^[2].
Kaurenoic acid (as a diterpene compound) is the main active ingredient in the root bark extract of A. senegalensis that exhibits anticonvulsant effects in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mice induced by LPS^[2]
Dosage:

1, 3, 10 mg/kg; single dose
Administration:

i.g.
Result:

Inhibited LPS-induced mechanical and thermal hyperalgesia, suppressed MPO activity, regulated the redox state of mouse paws, inhibited the production of pro-inflammatory/pain cytokines (such as TNF-α, IL-1β, and IL-33), and enhanced the production of anti-inflammatory/analgesic cytokine IL-10.

Chemical Information

CAS No. 6730-83-2
Appearance Solid
Molecular Weight 302.45
Formula C₂₀H₃₀O₂
Color White to off-white
SMILES

C[C@@]1(C(O)=O)CCC[C@@]2(C)[C@@]3([H])[C@@]4(CC([C@H](CC3)C4)=C)CC[C@]12[H]
Structure Classification
- Terpenoids
- Diterpenoids
Initial Source
- Plants
- Compositae
- Plants
- other families
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (330.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3063 mL

16.5317 mL

33.0633 mL

5 mM

0.6613 mL

3.3063 mL

6.6127 mL

10 mM

0.3306 mL

1.6532 mL

3.3063 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Carlos R Tirapelli, et al. Analysis of the mechanisms underlying the vasorelaxant action of kaurenoic acid in the isolated rat aorta. Eur J Pharmacol. 2004 May 25;492(2-3):233-41. [Content Brief]

[2]. Sergio M Borghi, et al. The diterpene from Sphagneticola trilobata (L.) Pruski, kaurenoic acid, reduces lipopolysaccharide-induced peritonitis and pain in mice. J Ethnopharmacol. 2021 Jun 12:273:113980. [Content Brief]

[3]. Theophine C Okoye, et al. Anticonvulsant effect of kaurenoic acid isolated from the root bark of Annona senegalensis. Pharmacol Biochem Behav. 2013 Aug:109:38-43. [Content Brief]

[4]. Mizokami SS, et al. Kaurenoic acid from Sphagneticola trilobata Inhibits Inflammatory Pain: effect on cytokine production and activation of the NO-cyclic GMP-protein kinase G-ATP-sensitive potassium channel signaling pathway. J Nat Prod. 2012 May 25;75(5):896-904. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3063 mL	16.5317 mL	33.0633 mL	82.6583 mL
	5 mM	0.6613 mL	3.3063 mL	6.6127 mL	16.5317 mL
	10 mM	0.3306 mL	1.6532 mL	3.3063 mL	8.2658 mL
	15 mM	0.2204 mL	1.1021 mL	2.2042 mL	5.5106 mL
	20 mM	0.1653 mL	0.8266 mL	1.6532 mL	4.1329 mL
	25 mM	0.1323 mL	0.6613 mL	1.3225 mL	3.3063 mL
	30 mM	0.1102 mL	0.5511 mL	1.1021 mL	2.7553 mL
	40 mM	0.0827 mL	0.4133 mL	0.8266 mL	2.0665 mL
	50 mM	0.0661 mL	0.3306 mL	0.6613 mL	1.6532 mL
	60 mM	0.0551 mL	0.2755 mL	0.5511 mL	1.3776 mL
	80 mM	0.0413 mL	0.2066 mL	0.4133 mL	1.0332 mL
	100 mM	0.0331 mL	0.1653 mL	0.3306 mL	0.8266 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Kaurenoic acid

Macrocyclic Compound Library

Antibacterial Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

Food-Sourced Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Natural Product Library

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Kaurenoic acid

Macrocyclic Compound Library

Antibacterial Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

Food-Sourced Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Natural Product Library

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Kaurenoic acid Related Classifications

HY-N1469 Related Classifications